Key Highlights

  • Acurx Pharmaceuticals shares are down 1.82% in pre-market trading to $1.62, pulling back after a sharp 17.86% close gain to $1.65 on Thursday.
  • The company announced that the FDA has conditionally accepted the proposed Brand name CIFBEZY for ibezapolstat, its lead antibiotic candidate, and that the USPTO has allowed the corresponding Trademark application.
  • Ibezapolstat is being developed for both acute treatment and reduction of recurrence of C. difficile infection (CDI), and is Phase 3 ready pending appropriate financing.
  • The FDA has indicated openness to an NDA filing based on a single Phase 3 trial supported by an open-label Phase 2 trial in patients with multiply-recurrent CDI, with patient enrollment for that trial expected to begin in the next few months.

Why the Stock Is Pulling Back

Acurx Pharmaceuticals (NASDAQ:ACXP) shares are trading lower in pre-market activity, consolidating after a sharp gain in the prior session. Acurx is a Staten Island, New York-based late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, including Clostridioides difficile, MRSA, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae.

Today's pullback follows news that the FDA has conditionally accepted the proposed brand name CIFBEZY for ibezapolstat, the company's lead antibiotic candidate, and that the USPTO has allowed the corresponding trademark application. While a genuinely positive regulatory and intellectual-property milestone, establishing a proprietary brand name is a preparatory commercial step rather than a clinical or approval milestone, and appears to be a more modest catalyst than what drove Thursday's larger rally. Commercial use of the name remains contingent on eventual approval of a U.S. New Drug Application.

Clinical Program Context

Ibezapolstat is being developed as an orally administered, Gram-Positive Selective Spectrum antibiotic for the acute treatment and reduction of recurrence of C. difficile infection, a condition the CDC has designated an urgent threat, with the disease associated with approximately 30,000 deaths annually in the United States. The drug is Phase 3 ready pending appropriate financing, and the FDA has indicated it is open to an NDA filing based on a single Phase 3 trial supported by an open-label Phase 2 trial in patients with multiply-recurrent CDI. Trial start-up activities for that Phase 2 study have been initiated, with patient enrollment expected to begin in the next few months.

Conclusion

Acurx Pharmaceuticals shares are modestly lower in pre-market trading as the stock consolidates after Thursday's sharp rally, even as the company continues to reach incremental regulatory and branding milestones for ibezapolstat. With the company's Phase 3 program still pending financing and the more consequential rCDI Phase 2 trial yet to begin enrollment, investors will likely be watching for updates on funding and trial initiation as the next meaningful catalysts.